CLGN Stock Analysis: Buy, Sell, or Hold?
CLGN - CollPlant Biotechnologies Ltd Ordinary Shares
$0.30
-0.01 (-3.73%)
▼
5d:
-5.91%
30d:
-4.45%
90d:
-29.46%
WAIT
LOW Confidence
Analysis Updated: Aug 24, 2026 12:00 AM ET
Earnings: Aug 19, 2026
0d
Get Alerted When CLGN Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: CLGN shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: CLGN shows conflicting indicators. Wait for confirmation before entering.
In-depth Analysis How we analyze
Valuation Analysis: CLGN is currently trading at $0.30, which is considered oversold relative to its 30-day fair value range of $0.30 to $0.33. From a valuation perspective, the stock is trading at a discount (Forward PE: -1.7) compared to its historical average (3.5). At these levels, the market is pricing in 0% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, CLGN is in a downtrend. Immediate support is located at $0.28, while resistance sits at $0.34. Short-term momentum is weak, with the stock down 3.7% recently.
Market Sentiment: CLGN scores 37/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $11.12 (+3596.8%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, CLGN is in a downtrend. Immediate support is located at $0.28, while resistance sits at $0.34. Short-term momentum is weak, with the stock down 3.7% recently.
Market Sentiment: CLGN scores 37/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $11.12 (+3596.8%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$0.30 -
$0.33
Company Quality Score
45/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
57.1%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (37/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-3.7%)
- BULLISH: Trading 3596.8% below Wall St target ($11.12)
- BULLISH: Market expects only 0% annual growth - appears undervalued
- WARNING: Composite score 45/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$0.30 -
$0.33
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$0.28
Resistance Level
$0.34
Current Trend
Downtrend
Technical data as of
Aug 24, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-1.67
Wall Street Target
$11.12
(+3596.8%)
Revenue Growth (YoY)
-96.4%
PE vs Historical
-1.7 vs 3.5
CHEAP
Share & Embed Analysis
Last updated: August 24, 2026 10:07 PM ET
Data refreshes hourly during market hours. Next update: 11:07 PM
Data refreshes hourly during market hours. Next update: 11:07 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CLGN showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
29 analysts |
$91 | 39 SELL |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$285 | 55 HOLD |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$108 | 53 HOLD |
|
NRIX
Nurix Therapeutics Inc |
STRONG BUY
18 analysts |
$34 | 46 HOLD |
|
INCY
Incyte Corporation |
HOLD
27 analysts |
$127 | 45 HOLD |
